Your browser doesn't support javascript.
loading
Novel concept of "sequential particle radiotherapy" with atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.
Komatsu, Shohei; Terashima, Kazuki; Ishihara, Nobuaki; Matsuo, Yoshiro; Kido, Masahiro; Yanagimoto, Hiroaki; Toyama, Hirochika; Tokumaru, Sunao; Okimoto, Tomoaki; Fukumoto, Takumi.
Afiliação
  • Komatsu S; Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan. komasho8@med.kobe-u.ac.jp.
  • Terashima K; Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan.
  • Ishihara N; Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
  • Matsuo Y; Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan.
  • Kido M; Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
  • Yanagimoto H; Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
  • Toyama H; Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
  • Tokumaru S; Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan.
  • Okimoto T; Department of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, Japan.
  • Fukumoto T; Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Surg Today ; 54(8): 972-976, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38436718
ABSTRACT
Owing to the high objective response rate of atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC), the concept of sequential conversion to local treatment has recently become mainstream. The conversion concept is mainly applied to Barcelona Clinic for Liver Cancer (BCLC) stage B cases, and radiotherapy is rarely considered as a conversion local treatment. We herein report three patients who were treated with the novel concept of "sequential particle radiotherapy," consisting of Atez/Bev therapy followed by particle radiotherapy (PRT) for HCC with advanced portal vein tumor thrombus (Vp3/4 PVTT). All patients achieved partial response radiologically and were switched to PRT. All patients were recurrence free at 1 year after the introduction of Atez/Bev therapy without any additional treatment. This upcoming combination strategy includes the advocacy of sequential concepts for BCLC stage C cases and the introduction of PRT as a local treatment after Atez/Bev.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Veia Porta / Carcinoma Hepatocelular / Anticorpos Monoclonais Humanizados / Bevacizumab / Neoplasias Hepáticas Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Veia Porta / Carcinoma Hepatocelular / Anticorpos Monoclonais Humanizados / Bevacizumab / Neoplasias Hepáticas Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article